SCHEMBL265356

SCHEMBL265356

Cn1c(=O)n(C)c2cc([N+](=O)[O-])ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.58
MAPT P10636 3/20 0.54
CYP19A1 P11511 1/20 0.49
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PKM P14618 2/20 0.47
CASP1 P29466 1/20 0.46
CASP3 P42574 1/20 0.46
CASP4 P49662 1/20 0.46
CASP7 P55210 1/20 0.46
CASP9 P55211 1/20 0.46
CASP6 P55212 1/20 0.46
ALDH1A1 P00352 3/20 0.46
BRD4 O60885 2/20 0.46
BRPF1 P55201 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30076419 0.84 MAPT (0.43) CYP1A2MAPTKDM4ELMNAHTT
SCHEMBL30349679 0.84 MEN1 (0.54) CYP1A2MAPTCYP19A1LMNANPSR1
SCHEMBL26086312 0.84 CYP1A2 (0.80) CYP1A2MAPTCYP19A1KDM4ELMNA
SCHEMBL28968226 0.84 CYP1A2 (0.80) CYP1A2MAPTCYP19A1KDM4ELMNA
SCHEMBL3302457 0.82 CYP1A2 (0.49) CYP1A2MAPTCYP19A1LMNANPSR1
SCHEMBL30349844 0.82 CYP1A2 (0.49) CYP1A2MAPTCYP19A1KDM4ELMNA
SCHEMBL14401725 0.81 SMN1; SMN2 (0.50) CYP1A2KDM4ELMNAHTTALDH1A1
SCHEMBL25439291 0.81 PIK3CA (0.50) CYP1A2MAPTCYP19A1CASP1CASP3
SCHEMBL28968228 0.81 PIK3CA (0.53) CYP1A2MAPTCYP19A1PKMALDH1A1
SCHEMBL4614270 0.80 MAPT (0.49) CYP1A2MAPTCYP19A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601335-B1 MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES WELLA AG (DE) 2008-03-19 EP claimed
US-20060162096-A1 Means and method for the simultaneous bleaching and dyeing of keratin fibres HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) 2006-07-27 US claimed
US-12590066-B2 Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 CN disclosed
CN-117820236-A Histone acetyltransferase small molecule inhibitor and preparation method and application thereof 复旦大学 2024-04-05 CN disclosed
US-20230295095-A1 NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-09-21 US disclosed
EP-4169905-A1 NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF Korea Institute of Science and Technology (KR) 2023-04-26 EP disclosed
CN-115867277-A Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof 韩国科学技术研究院 2023-03-28 CN disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
WO-2022237890-A1 AZEPINE-TYPE FUSED RING COMPOUND AND PHARMACEUTICAL USE THEREOF 中国医药研究开发中心有限公司 2022-11-17 WO disclosed
US-20060162096-A1 Means and method for the simultaneous bleaching and dyeing of keratin fibres HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) 2006-07-27 US disclosed
EP-1120421-B1 New triphendioxazine compounds CLARIANT FINANCE BVI LTD (VG) 2005-02-09 EP disclosed
US-6617453-B1 Preparing these triphendioxazine compounds by a cyclization step conducted in the presence of manganese dioxide and concentrated sulphuric acid. CLARIANT FINANCE (BVI) LIMITED (VG) 2003-09-09 US disclosed
EP-0911337-B1 Process for the preparation of triphendioxazine compounds CLARIANT FINANCE BVI LTD (VG) 2003-02-26 EP disclosed
US-6355795-B1 PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER AND ARE ALSO EASILY DISPERSIBLE CLARIANT FINANCE (BVI) LIMITED (BV) 2002-03-12 US disclosed
EP-1120421-A2 New triphendioxazine compounds Clariant Finance (BVI) Limited (VG) 2001-08-01 EP disclosed
EP-1120420-A2 New triphendioxazine compounds Clariant Finance (BVI) Limited (VG) 2001-08-01 EP disclosed
US-6255482-B1 PREPARING CHLORINE-CONTAINING TRIPHENDIOXAZINE COMPOUNDS USEFUL AS PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION, AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER CLARIANT FINANCE (BVI) LIMITED (VG) 2001-07-03 US disclosed
EP-0911337-A1 New triphendioxazine compounds Clariant Finance (BVI) Limited (VG) 1999-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060162096-A1 Means and method for the simultaneous bleaching and dyeing of keratin fibres KRT18, GPX4, NOX4 CYP1A2 3875/4885MAPT 1718/4885CYP19A1 2642/4885
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 CYP1A2 112/4885MAPT 3633/4885CYP19A1 1107/4885
US-12590066-B2 Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CLIC1 CYP1A2 385/4885MAPT 4672/4885CYP19A1 1550/4885
US-20230295095-A1 NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF CBR3, DBF4, DDT CYP1A2 766/4885MAPT 3518/4885CYP19A1 881/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT CYP1A2 194/4885MAPT 3061/4885CYP19A1 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.